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Background  
 
Symptom research in CKD1   
– Studied in isolation 
– The focus - on a single dimension  
– Missed severity and frequency   
– Limited to the dialysis population  
– Paucity of studies in CKD stage 4 & 5 
1. Almutary et al. J of Renal Care, 2013; 39(3):140-150. 
 
Background  
• High symptom burden1,2 
• Average of 6-20 symptoms1 
• Associated with ↓ HRQoL3,4 
• Interfere with treatment adherence 
• ↑ morbidity & mortality rates 
 
 
 
 
1. Almutary et al. J of Renal Care, 2013; 39(3):140-150.  
2. Caplin et al. Nephrol Dial Transplant, 2011; 26(8):2656-2663.  
3. Davison & Jhangri. J Pain  Symptom Management, 2010; 39(3):477-485. 
4. Yong et al. Palliative Med, 2009; 23(2):111-119.  
Importance of symptom assessment 
• Patients 
– To understand how symptom will change  
– Take informed decisions for treatment 
• Health-professionals 
– Understand how symptoms could interrelate, interact and 
cluster together 
– Prioritise management actions 
– Facilitate the implementation of symptom-alleviating 
therapies  
Main study  
Methods 
 
Cross-sectional design 
Convenience sample 
Inclusion criteria 
 Adults (≥18 years),  
 Diagnosed with CKD (eGFR <30 mls/min/m 2)  
 Willing to participate & able to provide consent  
 Able to communicate in Arabic 
Settings 
 Three hospitals, Jeddah, Saudi Arabia 
Instruments 
1. Demographic characteristics and clinical data 
2. Davies et al.’s comorbidity scores5 
3. CKD Symptom Burden Index  
– modified Dialysis Symptom Index 
• Added 2 symptoms (depression & nocturia) 
• Added 2 symptom dimensions (frequency & severity) 
• Added 3 free fields 
• Modified scale 0-10 
• Modified time – experienced symptom for last 4 weeks 
 
 5. Davies et al. Nephrol Dial Transplant, 2002; 17(6):1085-1092. 
CKD Symptom Burden Index  
 
CKD Symptom  
Burden Index 
(modified DSI) 
Palliative care Outcome 
Scale-Symptoms – renal 
(POS-S) 
No. of symptoms  32 + 3 free fields  17 + 3 free fields 
Ideal population  CKD stage 4 & 5 (HD & PD) CKD stage 5 (RSC) - only 
Prevalence       
Distress   (0-10)  (0-4) 
Severity   (0-10) ×   
Frequency   (0-10) ×   
Benefits   Comprehensive  
 Multidimensional 
 Clinical &  research 
applications 
 Different CKD populations  
 Simple   
 Quick  
 Easy to use 
 Clinical application  
Limitations     long  Tested only in RSC  
 Limited dimension 
 Sample n = 436 
 
  
 
 
107 
(24.5 %) 
329 
(75.5 %) 
Non-dialysis Dialysis
Results 
Stage 4 (69) 
Stage 5 (38) 
HD (287) 
PD (42) 
Demographic variables  Non-dialysis  Dialysis 
Age 51.60 ± 15.24 47.15 ±14.59 
Male 55.1 52.3 
Married 63.6 58.4 
Causes of CKD     
Diabetic nephropathy 33.6 30.7 
Hypertensive nephropathy 26.2 36.2 
Comorbid conditions      
0      74.8 31 
1-2 25.2 59.9 
≤ 3   0.00  9.1 
Clinical variables      
Albumin g/L 34.32 ± 4.63 33.14 ± 5.71 
Phosphate mmol/L 1.46 ± 0.32 1.56 ± 0.61 
Calcium mmol/L 2.22 ± 0.29 2.15 ± 0.3 
Haemoglobin g/L 108.15 ±17.16 107.95 ±17.09 
The mean scores of  symptom dimensions 
** p < 0.001 
  
CKD 
Mean (SD) 
Prevalence Distress Severity Frequency  
Stage 4 6.6 ± 5.45 20.35 ± 18.2 19.98 ± 19.4 25.24 ± 21.53 
Stage 5 7.16 ± 5.7 23.06 ± 24.36 22.09 ± 24.43 27.46 ± 26.66 
HD 15.16 ± 7.77** 72.24 ± 55.9** 70.39 ± 55.3** 73.5 ± 53.6** 
PD 9.76 ± 4.26 41.18 ± 24.76 34.1 ± 20.77 34.18 ± 19.78 
Symptom Prevalence  
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Correlation with Sample Characteristics  
• Women reported greater symptom distress, severity 
and frequency 
• No correlation between all symptom dimensions and 
– Albumin 
– Calcium 
– Phosphate 
– Haemoglobin  
Implications for Clinical Practice 
• Examine all symptoms’ dimensions 
– Most frequently reported symptoms are not necessarily the 
most severe or distressing symptoms 
• Fatigue assessment – PD patients  
– Development of nursing interventions that focus on energy 
conservation 
 
Implications for Clinical Practice 
• Assessment of psychological symptoms within non-
dialysis group  
– Routinely screening for psychological symptoms such as 
anxiety and depression  
• Gender diversity  
• Cultural backgrounds 
Implications for Clinical Practice 
• Research and clinical utility of CKD Symptom 
Burden Index  
– Can capture the multidimensional aspects of the symptoms 
– Can be used for the wider CKD population 
– Can be introduced into routine clinical practices 
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